ESMO-MCBS

ESMO-Magnitude of Clinical Benefit Scale

EVALUATION FORM 3 - ESMO-MCBS v2.0

For single-arm studies in "orphan diseases" and for diseases with "high unmet need" when primary outcome is PFS or ORR

Name of study:					
Study medicine:		**Indication:**			
First author:		**Year:**		**Journal:**	
Name of evaluator:					

GRADE 3	PFS ≥6 months	☐
	ORR (PR+CR) ≥60%	☐
	ORR (PR+CR) ≥20 - <60% AND duration of response ≥9 months	☐
GRADE 2	PFS ≥3 - <6 months	☐
	ORR (PR+CR) ≥40 - <60%	☐
	ORR (PR+CR) ≥20 - <40% AND duration of response ≥6 - <9 months	☐
GRADE 1	PFS 2 - <3 months	☐
	ORR (PR+CR) ≥20 - <40% AND duration of response <6 months	☐
	ORR (PR+CR) >10 - <20% AND duration of response ≥6 months	☐

Mark with √ if relevant

Preliminary magnitude of clinical benefit score	**3** ☐	**2** ☐	**1** ☐

CR, complete remission; ESMO-MCBS, European Society For Medical Oncology-Magnitude of Clinical Benefit Scale; ORR, overall response rate; PFS, progression-free survival; PR, partial response.

ESMO-MCBS

ESMO-Magnitude of Clinical Benefit Scale

Quality of life/Grade 3-4 toxicities assessment

Was QoL evaluated as secondary outcome?	☐
Does QoL show improvement?	☐
Are there ≥30% grade 3-4 toxicities impacting on daily well-being*?	☐

*This does not include alopecia, myelosuppression, but rather chronic nausea, diarrhoea, fatigue, etc.

Mark with √ if relevant

Adjustments

01. Downgrade 1 level if there are ≥30% grade 3-4 toxicities impacting on daily well-being*

02. Upgrade 1 level if improved QoL

03. Upgrade 1 level for confirmatory, adequately sized, phase 4 experience

Note: No more than 1 upgrade is possible.

*This does not include alopecia, myelosuppression, but rather chronic nausea, diarrhoea, fatigue, etc.

Adjusted magnitude of clinical benefit score	**4** ☐	**3** ☐	**2** ☐	**1** ☐

Note: Highest magnitude clinical benefit grade that can be achieved in form 3 is grade 4 and the lowest is 1.

Non-curative setting grading 5 and 4 indicate a substantial magnitude of clinical benefit.

QoL, quality of life.